Geode Capital Management
CAPR icon

Geode Capital Management’s Capricor Therapeutics CAPR Stock Holding History

Geode Capital Management’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$34M Buy
1,118,326
+100,994
+10% +$2.69M ﹤0.01% 1712
2025
Q4 		$29.4M Buy
1,017,332
+55,766
+6% +$728K ﹤0.01% 1797
2025
Q3 		$6.93M Sell
961,566
-1,514
-0.2% -$11.1K ﹤0.01% 2619
2025
Q2 		$9.56M Buy
963,080
+61,701
+7% +$652K ﹤0.01% 2395
2025
Q1 		$8.56M Buy
901,379
+21,911
+2% +$304K ﹤0.01% 2387
2024
Q4 		$12.1M Buy
879,468
+241,279
+38% +$4.23M ﹤0.01% 2244
2024
Q3 		$9.71M Sell
638,189
-3,384
-0.5% -$16.7K ﹤0.01% 2395
2024
Q2 		$3.06M Buy
641,573
+313,096
+95% +$1.75M ﹤0.01% 2973
2024
Q1 		$2.23M Buy
328,477
+12,279
+4% +$59.4K ﹤0.01% 3074
2023
Q4 		$1.55M Buy
316,198
+47,570
+18% +$155K ﹤0.01% 3189
2023
Q3 		$919K Sell
268,628
-29,694
-10% -$167K ﹤0.01% 3360
2023
Q2 		$1.43M Buy
298,322
+66,633
+29% +$293K ﹤0.01% 3221
2023
Q1 		$978K Buy
231,689
+5,579
+2% +$24K ﹤0.01% 3354
2022
Q4 		$872K Buy
226,110
+4,077
+2% +$19.5K ﹤0.01% 3411
2022
Q3 		$1.33M Buy
222,033
+15,970
+8% +$81.7K ﹤0.01% 3250
2022
Q2 		$719K Sell
206,063
-15,549
-7% -$55.2K ﹤0.01% 3567
2022
Q1 		$760K Buy
221,612
+16,040
+8% +$63.3K ﹤0.01% 3734
2021
Q4 		$602K Hold
205,572
– – ﹤0.01% 3944
2021
Q3 		$826K Buy
205,572
+20,582
+11% +$93.7K ﹤0.01% 3787
2021
Q2 		$948K Buy
184,990
+13,575
+8% +$57.5K ﹤0.01% 3637
2021
Q1 		$802K Buy
171,415
+49,569
+41% +$285K ﹤0.01% 3649
2020
Q4 		$417K Buy
121,846
+6,332
+5% +$27.5K ﹤0.01% 3645
2020
Q3 		$606K Buy
115,514
+84,129
+268% +$490K ﹤0.01% 3374
2020
Q2 		$144K Buy
31,385
+18,340
+141% +$79.9K ﹤0.01% 3759
2020
Q1 		$15K Hold
13,045
– – ﹤0.01% 4053
2019
Q4 		$16K Hold
13,045
– – ﹤0.01% 4172
2019
Q3 		$48K Hold
13,045
– – ﹤0.01% 4066
2019
Q2 		$43K Buy
13,045
+1,176
+10% +$4.92K ﹤0.01% 4096
2019
Q1 		$55K Hold
11,869
– – ﹤0.01% 4001
2018
Q4 		$48K Hold
11,869
– – ﹤0.01% 3996
2018
Q3 		$124K Hold
11,869
– – ﹤0.01% 3884
2018
Q2 		$159K Buy
11,869
+4,169
+54% +$56.7K ﹤0.01% 3778
2018
Q1 		$104K Hold
7,700
– – ﹤0.01% 3825
2017
Q4 		$121K Buy
7,700
+2,388
+45% +$51.7K ﹤0.01% 3777
2017
Q3 		$160K Hold
5,312
– – ﹤0.01% 3717
2017
Q2 		$44K Buy
5,312
+673
+15% +$12.3K ﹤0.01% 3977
2017
Q1 		$154K Buy
4,639
+246
+6% +$6.83K ﹤0.01% 3730
2016
Q4 		$116K Hold
4,393
– – ﹤0.01% 3758
2016
Q3 		$145K Hold
4,393
– – ﹤0.01% 3700
2016
Q2 		$173K Hold
4,393
– – ﹤0.01% 3635
2016
Q1 		$111 Hold
4,393
– – ﹤0.01% 3808
2015
Q4 		$134K Hold
4,393
– – ﹤0.01% 3809
2015
Q3 		$177K Hold
4,393
– – ﹤0.01% 3725
2015
Q2 		$221K Buy
+4,393
New +$276K ﹤0.01% 3547

Other funds holding CAPR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JHC
Jones Hill Capital New York $466M AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management's CAPR Position: Q1 2026 in Review

Geode Capital Management increased its Capricor Therapeutics (CAPR) stake by 9.9% in Q1 2026, buying an estimated $2.69M and bringing the position to 1,118,326 shares worth $34M. The position accounts for ﹤0.01% of the portfolio, ranked #1712.

Geode Capital Management first reported a position in CAPR in Q2 2015 and has held it in 44 quarters since. 177 funds tracked by Wall St. Rank hold CAPR as of Q1 2026.

  • Geode Capital Management held 1,118,326 shares of Capricor Therapeutics worth $34M as of Q1 2026.
  • Geode Capital Management bought 100,994 Capricor Therapeutics shares in Q1 2026, an estimated $2.69M.
  • Capricor Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #1712 holding.
  • Geode Capital Management first reported a position in Capricor Therapeutics in Q2 2015 and has held it in 44 quarters since.
  • 177 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.